Abstract
Understanding local-scale transmission dynamics of SARS-CoV-2 is crucial for planning effective prevention strategies. This study analyzed over 26,000 genomes and their associated metadata collected between January and October 2021 to explore the introduction and dispersal patterns of SARS-CoV-2 in Greater Houston, a major metropolitan area noted for its demographic diversity. We identified more than a thousand independent introduction events, resulting in clusters of varying sizes, with earlier clusters presenting larger sizes and posing greater control challenges. Characterization of the sources of these introductions showed that domestic origins were more significant than international ones. Further examination of locally circulating clusters across different subregions of Greater Houston revealed varied transmission dynamics. Notably, subregions that served as primary viral sources sustained the local epidemic effectively, evidenced by: (1) a smaller proportion of new cases driven by external viral importations, and (2) longer persistence times of circulating lineages. Overall, our high-resolution spatiotemporal reconstruction of the epidemic in Greater Houston enhances understanding of the heterogeneous transmission landscape, providing key insights into regional response strategies and public health planning.
Significance Statement The growing recognition of genome sequencing as critical for outbreak response has led to a rapid increase in the availability of sequence data. In this context, we put forward an analytical workflow within the Bayesian phylodynamic framework to identify and trace imported SARS-CoV-2 clusters using large-scale genome datasets. By utilizing metrics such as the Source-Sink Score, Local Import Score, and Persistent Time, our approach characterizes transmission patterns in each subregion and elucidates transmission heterogeneity. As new variants continue to emerge, the insights provided by our analysis are crucial for addressing the challenges of current and future pandemics effectively.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been funded in part from the National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services, under contract no. 75N93021C00018 (NIAID Centers of Excellence for Influenza Research and Response, CEIRR) and Centers for Disease Control and Prevention, Department of Health and Human Services, under contracts 75D30121C10133 and NU50CK000626. We acknowledge the GISAID contributors (acknowledgment table of genomes used is provided on our GitHub repository) for sharing genomic data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing Interest Statement: The authors declare that they have no conflict of interest.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
